Important note: Information in this article was accurate in December 2000. The state of the art may have changed since the publication date. IAVI Report - December 2000 / January 2001
David M. Gold
We would like to update you about a number of new developments at the IAVI Report.
Four and half years ago, IAVI published the first issue of the IAVI Report. Released at the 11th International Conference on AIDS in Vancouver, the publication set out to report on the emerging field of AIDS vaccine research throughout the world. Today, the IAVI Report reaches approximately 9,000 subscribers in more than 138 countries. Published six times a year, it is the world's only publication devoted solely to AIDS vaccine research and development.
IAVI created this publication to provide researchers, public health officials, policymakers and advocates with useful information on AIDS vaccine research and to focus critical attention on gaps in research and policy-making. The growing demand for the IAVI Report has demonstrated the keen interest in this field. We are proud to be cited as a source of information by a growing number of scientific journals, newspapers and magazines.
Beginning with the last issue, careful readers may have noticed that Patricia Kahn has become editor of the publication. This change follows my move to a newly created position at IAVI —-Vice-President of Policy and Public Sector Support. In this post, I am overseeing IAVI's growing work on vaccine access, encouraging industrial investment in AIDS vaccine development and increasing political and governmental support for AIDS vaccines in North America, Europe, Japan and Australia.
Having joined IAVI in 1999 as associate editor of the IAVI Report, Patricia brings a wealth of experience to the job. She is a researcher by training, and has worked in immunology, retrovirology and genomics, much of it at the European Molecular Biology Laboratory in Germany. Patricia began writing for Science in 1992 and later became a European correspondent for the magazine. Under her direction, the IAVI Report is expanding and instituting some important changes, which she will describe in the next issue.
Over these last four years, we have witnessed significant changes in AIDS vaccine research. The field is clearly advancing. But real advancements still take far too long. Each month we delay in developing and distributing an AIDS vaccine means 500,000 new HIV infections.
On a personal level, covering the field of AIDS vaccine research has been a very special opportunity for me. I have seen extraordinary individuals conducting, participating in and advocating for vitally important research. Most important, I now see signs that an AIDS vaccine is at least in sight.
David M. Gold
Founding Editor
001210
IAVI2000-120104
©2000. The IAVI Report.
ĘGiS is made possible through unrestricted grants from Roxane Laboratories, Inc., iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ĘGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. ĘGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ĘGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ĘGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.
